Baidu
map

Nat Commun:新多肽抑制剂可阻断新型冠状病毒繁衍

2014-02-18 健康报 健康报

复旦大学基础医学院医学分子病毒学教育部/卫生部重点实验室姜世勃教授课题组经1年多攻关,发现了一种可拮抗中东呼吸系统综合征冠状病毒的高效多肽抑制剂,该成果对进一步研究该病毒的入侵机制和研发防治该病毒的特效药物具有重大意义。相关研究论文日前发表在国际杂志《自然·通讯》上。 中东呼吸系统综合征(MERS,简称为玛斯)是由一种新型冠状病毒引起的新发传染病。玛斯2012年6月首现于沙特,目前确诊的玛斯病例

复旦大学基础医学院医学分子病毒学教育部/卫生部重点实验室姜世勃教授课题组经1年多攻关,发现了一种可拮抗中东呼吸系统综合征冠状病毒的高效多肽抑制剂,该成果对进一步研究该病毒的入侵机制和研发防治该病毒的特效药物具有重大意义。相关研究论文日前发表在国际杂志《自然·通讯》上。【原文下载】

中东呼吸系统综合征(MERS,简称为玛斯)是由一种新型冠状病毒引起的新发传染病。玛斯2012年6月首现于沙特,目前确诊的玛斯病例达178例,其中76人死亡。更为严峻的是,迄今,全世界尚无针对该病毒的特效药物和疫苗,且该病毒已具备有限人传人的能力。

姜世勃课题组与中科院生物物理所张荣光教授及香港大学袁国勇院士开展合作,首先对玛斯冠状病毒的融合和进入宿主细胞的机制进行了研究。研究人员将目标锁定在玛斯病毒中重要的S2蛋白核心功能区,以结晶技术获得了该核心功能区的三维空间结构图,并据此设计和合成了一系列病毒融合抑制多肽,终于发现其中一个多肽可有效抑制玛斯冠状病毒融合和进入宿主细胞。他们把这个多肽抑制剂命名为HR2P,因为它是来自于玛斯冠状病毒S2蛋白HR2功能区的一个蛋白质片段。

姜世勃说,多肽HR2P的作用机制为:玛斯病毒在感染人体细胞时,其关键蛋白——S2蛋白的HR2功能区必须与S2蛋白的HR1功能区相互作用后,才能“获准”进入人体细胞进行繁衍生殖。而他们发现的多肽HR2P能提前与玛斯病毒S2蛋白的HR1功能区结合,从而阻断了玛斯病毒的S2蛋白的HR2功能区与HR1功能区结合,使病毒无法再感染人体细胞。

姜世勃形象地比喻说:“玛斯病毒S2蛋白的HR1和HR2功能区就像人的左右手,其左右手必须紧紧地握在一起才能活下去。而我们发现的多肽HR2P就是故意制造出的一个一模一样的假右手,而这假右手可以提前握住真左手,造成‘紧握’的假象,导致真左手无法与真右手相握,从而失去活下去的条件。”姜世勃称之为“以其人之道,还治其人之身”的抗敌策略。

课题组还对多肽HR2P进行了改造,进一步提高了其抗病毒的活性和开发成安全、有特异性药物的潜力。

原始出处:

Lu L1, Liu Q1, Zhu Y2, Chan KH3, Qin L4, Li Y5, Wang Q5, Chan JF3, Du L6, Yu F6, Ma C6, Ye S4, Yuen KY3, Zhang R4, Jiang S7.Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.Nat Commun. 2014 Jan 28;5:3067. doi: 10.1038/ncomms4067.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709985, encodeId=be651e09985f9, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 10 03:16:00 CST 2014, time=2014-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851155, encodeId=f2f31851155eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 16 14:16:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879917, encodeId=5fdb18e991717, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 24 23:16:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086683, encodeId=60432086683c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 23 18:16:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530028, encodeId=3eeb1530028f8, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Feb 20 01:16:00 CST 2014, time=2014-02-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709985, encodeId=be651e09985f9, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 10 03:16:00 CST 2014, time=2014-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851155, encodeId=f2f31851155eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 16 14:16:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879917, encodeId=5fdb18e991717, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 24 23:16:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086683, encodeId=60432086683c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 23 18:16:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530028, encodeId=3eeb1530028f8, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Feb 20 01:16:00 CST 2014, time=2014-02-20, status=1, ipAttribution=)]
    2014-06-16 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709985, encodeId=be651e09985f9, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 10 03:16:00 CST 2014, time=2014-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851155, encodeId=f2f31851155eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 16 14:16:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879917, encodeId=5fdb18e991717, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 24 23:16:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086683, encodeId=60432086683c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 23 18:16:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530028, encodeId=3eeb1530028f8, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Feb 20 01:16:00 CST 2014, time=2014-02-20, status=1, ipAttribution=)]
    2014-08-24 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709985, encodeId=be651e09985f9, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 10 03:16:00 CST 2014, time=2014-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851155, encodeId=f2f31851155eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 16 14:16:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879917, encodeId=5fdb18e991717, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 24 23:16:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086683, encodeId=60432086683c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 23 18:16:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530028, encodeId=3eeb1530028f8, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Feb 20 01:16:00 CST 2014, time=2014-02-20, status=1, ipAttribution=)]
    2014-05-23 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709985, encodeId=be651e09985f9, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 10 03:16:00 CST 2014, time=2014-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851155, encodeId=f2f31851155eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 16 14:16:00 CST 2014, time=2014-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879917, encodeId=5fdb18e991717, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 24 23:16:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086683, encodeId=60432086683c8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri May 23 18:16:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530028, encodeId=3eeb1530028f8, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Feb 20 01:16:00 CST 2014, time=2014-02-20, status=1, ipAttribution=)]
    2014-02-20 fusion
Baidu
map
Baidu
map
Baidu
map